tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Gemzar'

Nuvilex’s Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive Big Pharma Target

Written by Ι Stock Market Media Group Staff — October 14, 2014

New York, NY – Nuvilex, Inc. (OTCQB: NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an application asking the agency to grant orphan drug status to its Cell-in-a-Box/ifosfamide combination for the rare disease.

The FDA’s orphan drug program designates a special status to drugs and biologics intended to treat, diagnose, or prevent diseases and disorders that affect fewer than 200,000 ...

Read More →
0

Nuvilex Adds World Renowned Oncologist and Gastroenterologist to Play Major Role in Late Phase Clinical Trial

SILVER SPRING, Md., May 1, 2014 — Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that world renowned oncologist and gastroenterologist Professor Dr. Matthias Lohr of the famed Karolinska Institute in Stockholm, Sweden, has agreed to play a major role in Nuvilex’s Phase 2b clinical trial in pancreatic cancer to be conducted in Australia, as well as other clinical studies and trials in which Nuvilex will be involved. Dr. ...

Read More →
0

Nuvilex, Inc. Could Obtain FDA Accelerated Approval After Phase 2b Clinical Trial

Nuvilex, Inc. Could Obtain FDA Accelerated Approval After Phase 2b Clinical Trial

Written by ι Stock Market Media Group Staff — April 17, 2014

Nuvilex, Inc. (OTCQB: NVLX) has once again delivered a major announcement as it advances its pancreatic cancer treatment toward late phase clinical trials. Nuvilex continues to put forth what is turning into a well thought out game plan for the future of treating advanced pancreatic cancer. It’s a game plan that could include obtaining accelerated FDA approval of its pancreatic cancer treatment if it can produce the same strong results in an announced ...

Read More →
0

Nuvilex Investors Should Read Between the Lines as Company Attracts World Renowned Oncologist

Written by ι Stock Market Media Group Staff — April 3, 2014

NEW YORK, NY–(Apr 3, 2014) – That loud noise you hear coming from Nuvilex, Inc. (OTCQB: NVLX) this week is the collective excitement of many investors after the company stated it would be working with Translational Drug Development or TD2 and Dr. Daniel Von Hoff, the world’s leading figure in pancreatic cancer, to develop its pancreatic cancer and other treatments utilizing Cell-in-a-Box® technology. Quite honestly Nuvilex may have just announced what ...

Read More →
0

Nuvilex, Inc. Lands Dr. Daniel Von Hoff to Lead Clinical Trials and TD2 as Contract Research Organization (CRO)

Written by ι Stock Market Media Group Staff — April 1, 2014

World Renowned Dr. Daniel Von Hoff to Lead Nuvilex’s Clinical Trials

Nuvilex Signs TD2 as Contract Research Organization (CRO)

  • Oncology Pioneer Dr. Daniel Von Hoff Agrees to Lead Nuvilex’s Pancreatic Cancer Clinical Trials
  • Dr. Von Hoff Developed Eli Lilly’s Gemzar®
  • Dr. Von Hoff Developed  Celgene’s Abraxane® 
  • Dr. Von Hoff is the World’s Leading Authority on Pancreatic Cancer & Now He will Lead Nuvilex’s Clinical Trials
  • Nuvilex Also Retains TD2 – The Precision Oncology CRO™ for Clinical Trials

The News Released This Morning by NVLX is Industry Changing and it will surely reverberate ...

Read More →
0

Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly

Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly

Written by ι Stock Market Media Group Staff — February 24, 2014

Lincoln Park Capital (LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB: NVLX) in exchange for an initial $2 million out of what can be viewed as a $27 million “pot of money” to advance the company’s late-phase pancreatic cancer clinical trials.  Notice we said restricted shares, that’s right, LPC has put a great deal of its money on the line with a number of built in protections for Nuvilex.  ...

Read More →
0
Page 1 of 4 1234
ContactUs.com